NOVARTIS PATENT CASE: A WIN-WIN SITUATION

The Supreme Court's judgment in the case of Swiss pharmaceutical major Novartis' patent for the cancer-fighting drug Glivec, has aroused mixed response throughout the world. Western pharmaceutical majors see a big hit, while the Indian counter parts making the generic version of the medici...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Management accountant 2013-10, Vol.48 (10), p.1183
Hauptverfasser:	Lavanya, K V N, Murthy, K Ch A V S N
Format:	Artikel
Sprache:	eng
Schlagworte:	Accountants Corporate profits Cost accounting Pharmaceutical industry Prescription drugs Supreme Court decisions
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!